A detailed history of Tower Research Capital LLC (Trc) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 706 shares of RVNC stock, worth $1,814. This represents 0.0% of its overall portfolio holdings.

Number of Shares
706
Previous 6,823 89.65%
Holding current value
$1,814
Previous $59,000 94.92%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.65 - $9.31 $28,444 - $56,949
-6,117 Reduced 89.65%
706 $3,000
Q4 2023

Feb 13, 2024

BUY
$5.81 - $11.2 $34,186 - $65,900
5,884 Added 626.62%
6,823 $59,000
Q3 2023

Nov 14, 2023

SELL
$11.47 - $25.07 $26,770 - $58,513
-2,334 Reduced 71.31%
939 $10,000
Q2 2023

Aug 14, 2023

BUY
$24.7 - $37.61 $22,254 - $33,886
901 Added 37.98%
3,273 $82,000
Q1 2023

May 09, 2023

SELL
$18.36 - $35.27 $13,053 - $25,076
-711 Reduced 23.06%
2,372 $76,000
Q4 2022

Feb 10, 2023

SELL
$18.32 - $30.66 $39,039 - $65,336
-2,131 Reduced 40.87%
3,083 $57,000
Q3 2022

Nov 10, 2022

BUY
$14.33 - $28.47 $26,238 - $52,128
1,831 Added 54.12%
5,214 $141,000
Q2 2022

Aug 15, 2022

BUY
$11.52 - $20.4 $27,912 - $49,429
2,423 Added 252.4%
3,383 $47,000
Q1 2022

May 12, 2022

SELL
$12.36 - $20.31 $6,044 - $9,931
-489 Reduced 33.75%
960 $19,000
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $12,298 - $27,507
-987 Reduced 40.52%
1,449 $24,000
Q3 2021

Nov 15, 2021

SELL
$25.78 - $33.21 $223,538 - $287,963
-8,671 Reduced 78.07%
2,436 $68,000
Q2 2021

Aug 16, 2021

BUY
$26.8 - $31.84 $118,724 - $141,051
4,430 Added 66.35%
11,107 $329,000
Q1 2021

May 17, 2021

BUY
$24.03 - $29.97 $51,328 - $64,015
2,136 Added 47.04%
6,677 $187,000
Q4 2020

Feb 16, 2021

SELL
$23.41 - $28.34 $196,995 - $238,481
-8,415 Reduced 64.95%
4,541 $129,000
Q3 2020

Nov 16, 2020

BUY
$23.23 - $34.3 $149,415 - $220,617
6,432 Added 98.59%
12,956 $326,000
Q2 2020

Aug 13, 2020

BUY
$12.6 - $26.55 $82,202 - $173,212
6,524 New
6,524 $159,000
Q1 2020

May 15, 2020

SELL
$12.46 - $27.81 $37,006 - $82,595
-2,970 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$11.66 - $20.15 $20,638 - $35,665
1,770 Added 147.5%
2,970 $48,000
Q3 2019

Nov 05, 2019

BUY
$10.22 - $14.5 $12,264 - $17,400
1,200 New
1,200 $16,000
Q3 2018

Nov 13, 2018

SELL
$23.55 - $30.1 $5,793 - $7,404
-246 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$27.45 - $33.35 $6,752 - $8,204
246 New
246 $7,000
Q1 2018

May 15, 2018

SELL
$29.15 - $37.4 $1,340 - $1,720
-46 Closed
0 $0
Q4 2017

Feb 09, 2018

SELL
$24.55 - $36.3 $76,203 - $112,675
-3,104 Reduced 98.54%
46 $2,000
Q3 2017

Nov 14, 2017

BUY
$22.55 - $28.1 $71,032 - $88,515
3,150
3,150 $87,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.